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a b s t r a c t
Maternal behavior and anxiety are potently modulated by the brain corticotropin-releasing factor (CRF)
system postpartum. Downregulation of CRF in limbic brain regions is essential for appropriate maternal
behavior and an adaptive anxiety response. Here, we focus our attention on arguably the most important
brain region for maternal behavior, the hypothalamic medial preoptic area (MPOA).
Within the MPOA, mRNA for CRF receptor subtype 1 (protein: CRFR1, gene: Crhr1) was more abun-
dantly expressed than for subtype 2 (protein: CRFR2, gene: Crhr2), however expression of Crhr1, Crhr2
and CRF-binding protein (protein: CRFBP, gene: Crhbp) mRNA was similar between virgin and lactating
rats. Subtype-speciﬁc activation of CRFR, predominantly CRFR1, in the MPOA decreased arched back
nursing and total nursing under non-stress conditions. Following acute stressor exposure, only CRFR1
inhibition rescued the stress-induced reduction in arched back nursing while CRFR1 activation prolonged
the decline in nursing. Furthermore, inhibition of CRFR1 strongly increased maternal aggression in the
maternal defense test. CRFR1 activation had anxiogenic actions and reduced locomotion on the elevated
plus-maze, however neither CRFR1 nor R2 manipulation affected maternal motivation. In addition,
activation of CRFR1, either centrally or locally in the MPOA, increased local oxytocin release. Finally,
inhibition of CRFBP (a potent regulator of CRFR activity) in the MPOA did not affect any of the maternal
parameters investigated.
In conclusion, activity of CRFR in the MPOA, particularly of subtype 1, needs to be dampened during
lactation to ensure appropriate maternal behavior. Furthermore, oxytocin release in the MPOA may
provide a regulatory mechanism to counteract the negative impact of CRFR activation on maternal
behavior.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The display of appropriate maternal behavior is the result of a
variety of peripartum adaptations, including activation and
inhibition of speciﬁc neurotransmitter systems in the brain. While
oxytocin and vasopressin typically promote maternal behavior, and
are hence up-regulated postpartum (e.g. Bosch and Neumann,
2008, 2012; Pedersen et al., 1994; van Leengoed et al., 1987), the
corticotropin-releasing factor (CRF) system impedes maternal
behavior and thus needs to be down-regulated (Gammie et al.,
2004; Klampﬂ et al., 2013, 2014, 2016a, b).
The CRF system consists of four ligands, CRF (protein: CRF, gene:
Crh) and the urocortins 1e3, which bind with different afﬁnities to
the two CRF receptors (protein: CRFR, gene: Crhr): CRFR1 and
CRFR2 (Reul and Holsboer, 2002a). In addition, activation of the
CRFR is regulated and, for the most part attenuated, by the
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secretory glycoprotein CRF-binding protein (protein: CRFBP, gene:
Crhbp) (Seasholtz et al., 2002; Sutton et al., 1995). CRF is the major
stress neuropeptide involved in cellular, neuroendocrine, and
behavioral responses to stress (Bale and Vale, 2004; Vale et al.,
1981). It is released upon stressor exposure and triggers the cen-
tral and peripheral stress response. Furthermore, CRF has anxio-
genic and pro-depressive actions, amongst others (Reul and
Holsboer, 2002a, b), which makes the CRF system one of the most
promising candidate systems for treating mood disorders such as
anxiety and depression.
During the postpartum period, activation of central CRFR
strongly impairs maternal care and maternal aggression thereby
inducing maternal neglect in lactating rats (Klampﬂ et al., 2013,
2014, 2016a), mice (D'Anna and Gammie, 2009; D'Anna et al., 2005;
Gammie et al., 2004), and marmoset monkeys (Saltzman et al.,
2011). These effects are observed not only by central activation of
CRFR via intracerebroventricular (ICV) administration of CRFR ag-
onists, but also by local stimulation of the CRFR1 and CRFR2 sub-
types in the lateral septum (D'Anna and Gammie, 2009; D'Anna
et al., 2005) and bed nucleus of the stria terminalis (BNST)
(Klampﬂ et al., 2014, 2016a).
The BNST and the adjacent medial preoptic area (MPOA),
together form the maternal ‘super-region’ for regulating maternal
behavior (Numan and Insel, 2003; Numan and Stolzenberg, 2009).
Given that the CRF family of neuropeptides act in both the anterior
and posterior BNST to inﬂuence maternal behavior (Klampﬂ et al.,
2014, 2016a), it seems intuitive that the CRF system may also play
a role in the counterpart of the maternal super-region, the MPOA.
Indeed, it is well established that the MPOA is crucial for the onset
and maintenance of maternal behavior, especially maternal care
andmaternal motivation (Numan and Stolzenberg, 2009). Here, the
nonapeptide oxytocin has been shown to promote maternal
behavior in several different species (Numan and Insel, 2003).
Oxytocinergic projections from the paraventricular nucleus are
thought to supply theMPOAwith constantly high concentrations of
oxytocin during lactation (Bosch and Neumann, 2012). In addition,
oxytocin receptors are substantially up-regulated in the MPOA
peripartum (Meddle et al., 2007), which facilitates ﬁnely-tuned
regulation of maternal care even under constant levels of intrace-
rebral oxytocin throughout mother-pup interactions (Bosch and
Neumann, 2012). Importantly, oxytocin directly interacts with the
CRF system, as oxytocin receptors are expressed on CRF neurons in
the BNST and CRFR2 are expressed on oxytocin neurons in the
paraventricular nucleus (Dabrowska et al., 2013), indicating a
reciprocal neuromodulatory role for both peptides.
In the present study, we hypothesized that like the BNST, the
MPOA CRF system is also involved in the regulation of maternal
behavior. Hence, we assessed the expression proﬁles of both CRFR
and CRFBP in the MPOA and examined the effects of modulating
CRFR or CRFBP in the MPOA under stress and non-stress conditions.
Furthermore, as one of the main mediators of maternal behavior in
the MPOA is the oxytocin system (Bosch and Neumann, 2012), we
hypothesized that local oxytocin release is affected by changes in
CRFR signaling.
2. Materials & methods
2.1. Animals and housing
Virgin female Sprague-Dawley rats (220e250 g; Charles River
Laboratories, Sulzfeld, Germany) were housed under standard
laboratory conditions (change of bedding once per week, RT
22± 2 C, 55% relative humidity, 12:12 h light/dark cycle, lights on
at 6 a.m.) with access to water and standard rat chow ad libitum. All
rats were initially housed in groups of 3e4 (for further details see
below). Female rats were mated with sexually experienced male
rats and pregnancy was conﬁrmed by the presence of sperm in
vaginal smears (pregnancy day (PD) 1). A separate, naïve cohort of
rats was used for each experiment, and in each case rats were
randomly assigned to the different treatment groups.
For experiment 1, virgin and lactating females were treated
similarly; virgins were single-housed 7 days prior to brain collec-
tion, consistent with the single-housing period of the lactating rats,
which were single-housed on PD 18 and killed 7 days later (lacta-
tion day (LD) 4). In experiments 2 and 5, females underwent sur-
gery on PD 18 and were subsequently single-housed to guarantee
recovery and undisturbed parturition (Klampﬂ et al., 2013). In ex-
periments 3 and 4, rats were single-housed on PD 18 and under-
went surgery on LD 1. On the day of birth, litters of all dams were
culled to eight pups of mixed sexes. All rats were handled twice
daily on PD 16e17 and during the single-housing period (except on
the day of surgery and birth) to reduce non-speciﬁc stress re-
sponses during the experiments (Neumann et al., 1998).
For the maternal defense test, naïve virgin female Wistar rats
(200e220 g; Charles River Laboratories) were used as intruders at
random stages of their estrous cycle. Intruder rats were kept group-
housed in a separate room to avoid olfactory recognition (Bosch,
2013).
The experiments were approved by the Committee on Animal
Health and Care of the local government and conformed with the
European Directive (2010/63/EU) on the ethical use of animals. All
reasonable efforts were made to minimize the number of rats used
and their suffering.
2.2. Behavioral tests
All tests were performed between 8 a.m. and 3 p.m. during the
light phase of the cycle. In experiments with repeated drug infusion
(experiments 2 and 5), rats received the same drug throughout the
experiment. After infusion, dams were immediately returned to
their home cage.
2.2.1. Maternal care
Maternal care was monitored before and after drug infusion
under non-stress and stress conditions (maternal defense test)
(Klampﬂ et al., 2013, 2014, 2016a, b). Observations were made for
10 s every 2nd min in 30min blocks according to an established
protocol (Bosch and Neumann, 2008). The main parameter for the
quality of maternal care was the occurrence of arched back nursing
(ABN) (Bosch, 2011), an active nursing posture where the dam is
engaged in a quiescent kyphosis (Stern and Johnson, 1990). Other
behavioral parameters scored were hovering over the pups and
blanket nursing posture, which together with ABNwere counted as
total nursing, thereby indicating the quantity of maternal care
(Klampﬂ et al., 2014). Pup retrieval/mouthing and licking/grooming
(LG) were also scored. Additionally, non-maternal behaviors were
quantiﬁed, i.e. locomotion (including digging/burrowing and cage
exploration), self-grooming, and sleeping/resting, which were
summed up and are presented as ‘off-nest behavior’.
2.2.2. Maternal motivation
The dams' maternal motivation was tested in the modiﬁed pup
retrieval test (PRT) as described previously (Bayerl et al., 2016).
Brieﬂy, dams were habituated to a red Perspex house for 150min
the day prior to the PRT. On the day of testing, the pups were
separated from the dam for 60min, during which the red house
was re-introduced to the dam's cage. Afterwards, the house and the
dam were transferred to a plastic testing box
(54 cm 34 cm 31 cm), which contained some bedding and the
pups. Here, the number of pups retrieved into the house within the
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15-min testing period was counted as well as the latencies to
retrieve the ﬁrst and the last pup.
2.2.3. Maternal aggression
To assess maternal aggression, the maternal defense test was
performed in a separate room, to which the dams were transported
60min prior to the test. After drug infusion, the lactating resident
(in the presence of the litter) was confronted with an unknown
virgin female intruder in her home cage for 10min as described
previously (Bosch et al., 2005; Neumann et al., 2001). The dam's
behavior was videotaped for subsequent analysis by an experi-
enced observer blind to the treatment using JWatcher (http://www.
jwatcher.ucla.edu/). The following behavioral parameters were
scored: total number of attacks, latency to ﬁrst attack, lateral threat,
keep down, and offensive upright as well as non-aggressive be-
haviors (for detailed description see (Bosch, 2013)).
2.2.4. Anxiety-related behavior
Anxiety-related behavior was tested on the elevated plus-maze
(EPM) as previously described (Neumann et al., 2000; Pellow et al.,
1985). Brieﬂy, the plus-shaped maze consists of two open arms
(50 cm 10 cm, 80 lux) and two closed arms (50 cm 10 cm x
30 cm, 10 lux) surrounding a neutral square-shaped central zone
(10 cm 10 cm, 65 lux) and is elevated 82 cm above the ﬂoor. After
drug infusion, the rats were placed in the neutral zone to freely
explore the maze for 5min. Both fore-paws needed to be on an
open arm to be counted as open arm time. All four paws needed to
be in an open arm to be counted as full open arm entry. The per-
centage of time spent on the open arm versus all areas (open arm,
closed arm, and neutral zone) and the number of full open arm
entries were indicators for anxiety-related behavior. The number of
closed arm entries was used to measure locomotion (Neumann
et al., 2000).
2.3. Experimental design
2.3.1. Experiment 1: Expression of Crhr and Crhbp mRNA in the
MPOA of virgin and lactating rats
To compare the effect of reproductive status on Crhr1, Crhr2, and
Crhbp mRNA expression in the MPOA, 29 virgin and lactating rats
were killed in themorning of LD 4 (CrhrmRNA), LD 7 (CrhbpmRNA)
or equivalent in virgin rats, i.e. after 7 days of single-housing under
basal conditions by conscious decapitation as anesthesia can affect
central peptide content as well as activate the HPA axis (Bekhbat
et al., 2016; Smagin and Goeders, 2004; van Duinen et al., 2005).
The brains were rapidly removed, ﬂash frozen in n-methylbutane
on dry ice, and stored at 20 C until further processing. Later,
frozen brains were sectioned at 16 mm using a cryostat (Model
CM3050S Leica Microsystems GmbH, Nussloch, Germany), moun-
ted on polysine slides, and stored at20 C until further processing.
Crhr1, Crhr2, and Crhbp mRNA in situ hybridization was per-
formed using an established protocol with previously described
cRNA probes for Crhr1, Crhr2 (Brunton et al., 2009, 2011), and Crhbp
(Speert et al., 2002; Stinnett et al., 2015). Autoradiograms of the
MPOA (Bregma0.24mm to0.6mm (Paxinos andWatson,1998))
were analyzed with ImageJ (V1.46, NIH image software) as previ-
ously described (Brunton et al., 2011). Measurements were made
bilaterally over six sections per rat. Brain sections hybridized with
35S-UTP-labeled cRNA sense probes (negative controls) showed no
signal above background.
2.3.2. Experiments 2 and 5: Pharmacological manipulation of CRFR
and CRFBP in the MPOA of lactating rats
On PD 18, 54 females (experiment 2: n¼ 34; experiment 5:
n¼ 20) were implanted bilaterally with 23 G guide cannula
targeting the MPOA (0.4mm caudal, 0.8mm lateral, 6.8mmventral
to bregma (Paxinos andWatson,1998)) under inhalation anesthesia
(Isoﬂurane; Baxter Germany GmbH, Unterschleibheim, Germany)
and sterile conditions as described earlier (Bosch et al., 2010).
Substances were infused using a 27 G infusion cannula. In experi-
ment 2, lactating rats received one of the following treatments
10 min before testing: (i) VEH (0.5 ml of sterile Ringer's
solution þ 4% DMSO; pH 7.4; B. Braun Melsungen, Melsungen,
Germany), (ii) CRFR1 agonist, human/rat CRF (h/rCRF; 1 mg/0.5 ml;
Tocris Bioscience, Ellisville, Missouri, USA), (iii) CRFR1 speciﬁc
antagonist, CP-154,526 (0.4 mg/0.5 ml; Tocris Bioscience), (iv) CRFR2
speciﬁc agonist, human Ucn 3 (hUcn3; also known as stresscopin;
3 mg/0.5 ml; Phoenix Pharmaceuticals, Karlsruhe, Germany), or (v)
CRFR2 speciﬁc antagonist (astressin-2B; 4 mg/0.5 ml; Sigma-Aldrich,
Steinheim, Germany). In experiment 5, lactating rats received
either (i) VEH (0.5 ml of sterile Ringer's solution; pH 7.4; B. Braun
Melsungen) or (ii) the CRFBP inhibitor CRF(6-33) (5 mg/0.5 ml;
Bachem, Bubendorf, Switzerland) 20min before testing. Doses and
the lag time between the infusion and behavioral testing were
chosen based on previous studies (Klampﬂ et al., 2014, 2016a, b;
Zorrilla et al., 2001).
Maternal care was observed in the same rats under non-stress
conditions (LD 1) and stress conditions (LD 7) in their home cage
in the colony room. Under non-stress conditions, dams were
observed from 8 a.m.e9 a.m., followed by treatment infusion and
subsequent observation for a further 120min. In addition, 5 h after
the infusion (2 p.m.e3 p.m.), maternal care was monitored again to
assess any potential long-lasting effects of the drug treatment. On
LD 7, dams were observed from 8 a.m.e9 a.m. in their colony room
before being moved to the test room. At 10 a.m., dams were VEH/
drug-infused, exposed to stress using the maternal defense test
and immediately afterwards returned to the colony room, where
maternal care was observed for a further 60min to assess the ef-
fects of the preceding stressor on maternal care. Additionally,
maternal motivation (LD 3), anxiety-related behavior (LD 5), and
maternal aggression (LD 7) were assessed as described in 2.2.
2.3.3. Experiment 3: Pharmacological ICV CRFR activation and
simultaneous microdialysis in the MPOA of lactating rats
On LD 1, 22 females were implanted with a 21 G guide cannula
targeting the left lateral ventricle (1.0mm caudal, 1.6mm lateral,
2.1mm ventral to bregma (Paxinos and Watson, 1998)) and a
microdialysis probe (molecular cut-off: 18 kDa; Hemophan, Gam-
bro Dialysatoren, Hechingen, Germany) targeting the right MPOA
(0.4mm caudal, 0.9mm lateral, 8.8mm ventral to bregma (Paxinos
andWatson, 1998)) under inhalation anesthesia (Isoﬂurane; Baxter
Germany GmbH) and sterile conditions as described earlier (Bosch
et al., 2010).
On LD 3, the inﬂow adapter of the microdialysis probe was
connected via PE-20 tubing to a syringe mounted onto a micro-
infusion pump. The outﬂow adapter was attached to a 1.5 ml
collection tube containing 10 ml 0.1 N HCl. The probe was ﬂushed at
a rate of 3.3 ml/minwith sterile Ringer's solution (pH 7.4) for 90 min
before 30 min sample collections commenced. Starting at 10 a.m.,
samples 1 and 2 were collected under basal conditions. Afterwards,
dams were infused ICV with either (i) VEH (5 ml sterile Ringer's
solution þ 4% DMSO, pH 7.4), (ii) CRFR1 agonist h/rCRF (1 mg/5 ml),
or (iii) CRFR2 speciﬁc agonist hUcn3 (3 mg/5 ml). Samples 3e5 were
collected during the 90-min period following drug injection.
Additionally, maternal care was observed throughout the entire
sampling period. All microdialysates were immediately frozen on
dry ice and stored at 80 C until quantiﬁcation of oxytocin (see
2.4).
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2.3.4. Experiment 4: Intra-MPOA CRFR1 agonist retrodialysis in
lactating rats
Separate groups of lactating rats (n¼ 14) were implanted
unilaterally with a microdialysis probe targeting the right MPOA on
LD 1. Microdialysis was performed on LD 3 as described in 2.3.3 for
experiment 3, except that the perfusion rate was 1 ml/min (Bosch
et al., 2005).
Starting at 10 a.m., samples 1 and 2 were collected under basal
conditions 30 min apart. Next, the syringes containing Ringer's
solution were swapped for those ﬁlled with either (i) VEH (sterile
Ringer's solution þ 4% DMSO, pH 7.4) or (ii) CRFR1 agonist h/rCRF
(0.05 mg/ml/min) for 30 min (sample 3). Syringes were then
switched back to those containing sterile Ringer's solution and
samples 4 and 5 were collected 30 min apart. Microdialysate
samples were immediately frozen on dry ice and stored at 80 C
until quantiﬁcation of oxytocin (see 2.4).
2.4. Radioimmunoassay for oxytocin in microdialysates
Oxytocin peptide content was measured in lyophilized di-
alysates by a highly sensitive and selective radioimmunoassay
(detection limit: 0.1 pg/sample; cross reactivity of the antisera with
other related peptides< 7%; RIAgnosis, Munich, Germany; for de-
tails see (Landgraf et al., 1995)).
2.5. Histology
All rats were killed at the end of the experiments (experiment 1:
decapitation without anesthesia; experiments 2 and 5: LD 7, CO2
overdose; experiment 3: LD 4, CO2 overdose; experiment 4: LD 3,
CO2 overdose), and brains were collected and ﬂash frozen in n-
methylbutane for histological veriﬁcation of correct cannula
placement. To identify implantation sites, 0.5 ml ink was infused
post-mortem into the brain via the cannula (experiments 2 and 3;
Pelikan Ink 4001, Hanover, Germany; diluted 1:20 in Ringer's so-
lution). Brains were then removed, ﬂash frozen, cut in 40 mm cor-
onal sections, and mounted on slides. Brains were checked for
potential diffusion outside the MPOA according to an established
protocol (Klampﬂ et al., 2014, 2016a, b) and were excluded from
analysis if any staining was detected beyond theMPOA. Brains from
experiments 3 and 4 were removed, ﬂash frozen, sectioned, and
mounted on slides. Brain sections from all experiments were Nissl
stained to locate the tip of the infusion cannula/microdialysis
probe. Only rats identiﬁed as having correctly positioned implants
were included in the statistical analysis.
2.6. Statistical analysis
Data were analyzed using either an independent t-test, paired t-
test, two-way ANOVA (factors: brain site, reproductive status), or
two-way repeated measures (RM) ANOVA (factors: time x treat-
ment) followed by Fisher's LSD post hoc test. For all statistical an-
alyses, the software package SPSS 24.0 (IBM, Armonk, NY, USA) was
used. Data are presented as group means ± SEM, and p  0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Experiment 1: Expression of Crhr1, Crhr2, and Crhbp mRNA in
the MPOA of virgin and lactating rats
Crhr1 and Crhr2 mRNA expression in the MPOA did not differ
between virgin and lactating rats (Fig. 1 left); however, levels of
Crhr1 mRNA expression were signiﬁcantly greater than Crhr2
mRNA, independent of reproductive status (two-way ANOVA;
factor: receptor subtype; F1,20¼ 24.66, p< 0.01; Fig. 1 left). There
were no differences in Crhbp mRNA expression in the MPOA be-
tween virgin and lactating rats (Fig. 1 right).
3.2. Experiment 2: Pharmacological manipulation of CRFR in the
MPOA of lactating rats
3.2.1. Maternal care under non-stress conditions
ABN: ABN signiﬁcantly differed over time between the groups
(two-way RM ANOVA; F24,174¼1.81, p¼ 0.01; Fig. 2A left).
Compared to basal levels, ABN was decreased at t 0 min in the VEH
(p < 0.01) and both agonist groups (CRFR1 agonist: p¼ 0.03; CRFR2
agonist: p ¼ 0.01), but not the antagonist-treated groups. ABN was
signiﬁcantly lower in the CRFR1 agonist-treated dams after infu-
sion, i.e. at t 0 min, t þ30 min, t þ60 min, and t þ90 min, compared
with the VEH-treated group (p < 0.01, in each case). Furthermore,
ABN was lower in the CRFR2 agonist-treated dams at t 0 min and
t þ30 min (p ¼ 0.02, in each case) compared to the VEH group. No
differences were found between the antagonist-treated groups and
the VEH group at any time points following the drug infusion.
Nursing: Nursing differed over time between the groups (two-
way RMANOVA; F24, 174¼1.89, p¼ 0.01; Fig. 2A right). Compared to
basal levels, nursing was decreased at t 0 min in both agonist-
treated groups (p < 0.01, in each case). Following the infusion,
nursing was persistently lower in the CRFR1 agonist-treated dams
(t 0 min e t þ300 min: p < 0.01, t þ330 min: p ¼ 0.05), compared
with the VEH group. Nursing was also lower in the CRFR2 agonist
group, compared with the VEH group, however the effect was more
transient (t 0 min, p < 0.01; t þ30 min, p ¼ 0.02). The amount of
nursing in the antagonist-treated dams did not differ from the
control rats.
Other maternal behavior: No signiﬁcant differences were
observed in other maternal behaviors, i.e. pup retrieval/mouthing
and LG (data not shown).
Non-maternal behavior: Signiﬁcant interactions were found for
overall off-nest behaviors (two-way RM ANOVA; F24,174¼1.78,
p¼ 0.02), locomotion (F24,174¼1.79, p¼ 0.01), and self-grooming
(F24,174¼ 4.01, p< 0.01; Table 1). Both the CRFR1 and CRFR2
agonist-treated dams showed more off-nest behavior (p < 0.01, in
each case), locomotion (CRFR1 agonist: p < 0.01; CRFR2 agonist:
p ¼ 0.01), and self-grooming (p < 0.01, in each case) at t 0 min
compared to basal. Also, the CRFR2 antagonist-treated rats
exhibited more off-nest behavior at t 0 min compared to basal
(p ¼ 0.04). Compared to the VEH-treated dams, the CRFR1 agonist-
treated dams displayed more off-nest behavior from t 0 min to
t þ300 min, locomotion from t 0 min to t þ330 min, and self-
Fig. 1. Crhr1, Crhr2 (left) and Crhbp (right) mRNA expression in the MPOA in virgin
and lactating rats. Data are presented as mean grain area þ SEM. n ¼ 5e10 per group.
*p < 0.05 versus Crhr1 (two-way ANOVA; factors: reproductive status, brain site).
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grooming from t 0 min to t þ90 min (p < 0.01, in each case). The
CRFR2 agonist-treated dams exhibited more off-nest behavior at t
0 min (p < 0.01) and t þ30 min (p ¼ 0.01), compared with the VEH
group. There was no signiﬁcant effect of the CRFR1 antagonist on
any of the non-maternal behaviors analyzed under non-stress
conditions and no signiﬁcant differences were detected for
sleeping/resting between any of the treatment groups (Table 1).
3.2.2. Maternal care under stress conditions
ABN: There was a signiﬁcant effect of time (two-way RM
ANOVA; F2,50¼ 9.72, p< 0.01; Fig. 2B left), but not of treatment.
Separate statistics (paired t-test) showed that ABN decreased after
the infusion/maternal defense test in all groups (VEH: p¼ 0.05;
CRFR1 agonist, CRFR2 antagonist: p< 0.01, in each case), except the
CRFR1 antagonist- (p¼ 0.7) and CRFR2 agonist-treated dams
(p¼ 0.1) at t 0min versus basal.
Nursing: Nursing signiﬁcantly changed over time between the
groups (two-way RM ANOVA; F8,50¼ 4.48, p< 0.01; Fig. 2Bmiddle).
Stress exposure (maternal defense test) triggered a reduction in
nursing in all groups at t 0 min compared to basal levels (VEH,
CRFR1 agonist, CRFR1 antagonist: p < 0.01, in each case; CRFR2
agonist: p ¼ 0.01; CRFR2 antagonist: p ¼ 0.02), which had recov-
ered by t þ30 min in all groups except for the CRFR1 agonist-
treated dams (p < 0.01 vs. VEH).
Other maternal behavior: LG differed over time between the
groups (two-way RM ANOVA; F8,50¼ 2.58, p¼ 0.01; Fig. 2B right).
The CRFR1 agonist-treated rats showed increased LG at t 0 min
(p < 0.01) compared to basal levels and at t þ30 min (p < 0.01)
compared to the VEH group. No effect was found for pup retrieval/
mouthing (data not shown).
Non-maternal behavior: Signiﬁcant interactions were found for
overall off-nest behavior (two-way RM ANOVA; F8,50¼ 2.05,
p¼ 0.05) and self-grooming (F8,50¼ 2.29, p¼ 0.03; Table 2). All
groups except the CRFR2 antagonist-treated dams showed more
off-nest behavior at t 0 min compared to basal levels (VEH, CRFR1
agonist, CRFR1 antagonist: p < 0.01, in each case; CRFR2 agonist:
p ¼ 0.03). In addition, the CRFR1 agonist- and CRFR1 antagonist-
treated rats exhibited signiﬁcantly more self-grooming at t 0 min
compared to basal conditions (CRFR1 agonist: p < 0.01; CRFR1
antagonist: p ¼ 0.01). The CRFR1 agonist-treated dams showed
more off-nest behavior at tþ30min (p¼ 0.02) and self-grooming at
t 0 min and t þ30 min (p < 0.01, in each case). No other changes
were detected in any of the treatment groups.
3.2.3. Maternal motivation
None of the CRFRmanipulations affectedmaternal motivation in
Fig. 2. Effect of pharmacological manipulation of MPOA CRFR1 or CRFR2 on maternal care under (A) non-stress conditions on LD 1 or (B) stress conditions on LD 7. Arched
back nursing (ABN), total nursing, and licking/grooming (LG) were scored for 60 min before (basal) and (A) for 90 min after infusion (t 0 to t þ90) as well as for 60 min in the
afternoon (t þ300 to t þ330) or (B) for 60 min after infusion combined with the maternal defense test (t 0 to t þ30). Dams received an acute bilateral infusion of either (i) vehicle
(VEH), (ii) CRFR1 agonist (ago; h/rCRF), (iii) CRFR1 antagonist (ant; CP-154,526), (iv) CRFR2 ago (hUcn3/stresscopin), or (v) CRFR2 ant (astressin-2B) into the MPOA. Data are
presented as group means þ SEM. n ¼ 6e8 rats per group. **p  0.01, *p  0.05 versus VEH-treated group; þþ p  0.01, þ p  0.05 versus basal levels in the same group (two-way
RM ANOVA).
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the PRT (data not shown).
3.2.4. Maternal aggression
The number of attacks (one-way ANOVA; F4,29¼ 5.36, p< 0.01;
Fig. 3 left) and the sum of aggressive behaviors (F4,29¼ 9.89, p <
0.01; Fig. 3 right) differed between the groups. Both measures for
maternal aggressive behavior were signiﬁcantly greater in the
CRFR1 antagonist-treated dams (p< 0.01, in each case), compared
with all other groups.
3.2.5. Anxiety-related behavior
On the EPM, the percentage of time spent on the open arms
(one-way ANOVA; F4,29¼ 2.99, p¼ 0.04; Fig. 4 left) and the number
of full open arm entries (F4,29¼ 2.83, p¼ 0.05; Fig. 4 middle)
signiﬁcantly differed between the groups. The CRFR1 agonist-
treated dams spent signiﬁcantly less time on the open arms
(p¼ 0.05) and made fewer full open arm entries (p¼ 0.02)
compared with the VEH-treated rats. Entries onto the closed arms
(indicating locomotor activity) did not differ between groups when
data was analyzed using a one-way ANOVA; however separate
statistical analysis revealed that the CRFR1 agonist-treated dams
made fewer closed arm entries indicating decreased locomotor
activity compared to the VEH-treated dams (independent t-test;
t10¼ 2.93, p¼ 0.02; Fig. 4 right).
3.3. Experiment 3: Effects of ICV CRFR activation on maternal care
and intra-MPOA oxytocin release in lactating rats
3.3.1. Maternal care
ABN: There was a signiﬁcant effect of time (two-way RM
Table 1
Effect of pharmacological manipulation of MPOA CRFR1 or CRFR2 on non-maternal behaviors under non-stress conditions on LD 1.
Behavior Group Occurrence [n]
Basal 0min þ30 min þ60 min þ90 min þ300 min þ330 min
Off-nest VEH 1.1± 0.5 1.6± 0.8 0.1± 0.1 2.1± 1.2 1.7± 1.5 0.9± 0.5 2.7± 2.0
CRFR1 ago 1.5± 0.7 11.8 ± 1.0**þþ 7.8 ± 2.3** 9.7 ± 2.6** 8.8 ± 2.8** 7.8 ± 2.7** 7.8± 2.2
CRFR1 ant 1.3± 0.4 3.3± 1.5 0.8± 0.6 1.8± 0.8 0.5± 0.3 1.2± 0.6 1.3± 0.8
CRFR2 ago 0.7± 0.2 8.9 ± 2.0**þþ 6.0 ± 2.5* 1.4± 0.6 0.9± 0.3 2.9± 2.0 2.6± 1.8
CRFR2 ant 1.0± 0.5 4.7± 2.2þ 1.4± 0.6 1.1± 1.0 0.1± 0.1 0.1± 0.1 3.6± 1.8
Locomotion VEH 0.6± 0.4 1.0± 0.6 0.0± 0.0 0.9± 0.4 1.0± 0.8 0.4± 0.3 0.3± 0.2
CRFR1 ago 0.2± 0.1 7.3 ± 1.1**þþ 4.5 ± 1.6** 6.5 ± 1.6** 5.8 ± 2.1** 5.8 ± 2.5** 6.5 ± 2.0**
CRFR1 ant 0.7± 0.3 2.5± 1.3 0.2± 0.2 1.2± 0.4 0.2± 0.2 0.2± 0.2 0.8± 0.3
CRFR2 ago 0.4± 0.1 2.8± 0.7þ 1.4± 0.7 0.5± 0.3 0.9± 0.3 0.0± 0.0 0.1± 0.1
CRFR2 ant 0.6± 0.3 1.4± 0.7 0.4± 0.3 0.9± 0.7 0.1± 0.1 0.1± 0.1 1.0± 0.4
Self-grooming VEH 0.3± 0.1 0.4± 0.3 0.1± 0.1 0.4± 0.3 0.0± 0.0 0.0± 0.0 0.3± 0.2
CRFR1 ago 0.2± 0.1 3.5 ± 0.8**þþ 2.7 ± 0.5** 1.7 ± 0.6** 1.1 ± 0.5** 0.5± 0.2 0.5± 0.5
CRFR1 ant 0.6± 0.2 0.6± 0.3 0.5± 0.3 0.3± 0.2 0.3± 0.3 0.3± 0.3 0.0± 0.0
CRFR2 ago 0.2± 0.1 1.4± 0.4þþ 0.3± 0.2 0.0± 0.0 0.0± 0.0 0.3± 0.2 0.5± 0.3
CRFR2 ant 0.1± 0.1 0.7± 0.4 0.3± 0.2 0.0± 0.0 0.0± 0.0 0.0± 0.0 1.0± 0.5
Sleeping/
resting
VEH 0.0± 0.0 0.0± 0.0 0.0± 0.0 0.4± 0.4 0.0± 0.0 0.4± 0.4 2.1± 2.1
CRFR1 ago 0.0± 0.0 0.0± 0.0 0.0± 0.0 0.2± 0.2 0.8± 0.8 0.0± 0.0 0.0± 0.0
CRFR1 ant 0.0± 0.0 0.0± 0.0 0.0± 0.0 0.0± 0.0 0.0± 0.0 0.7± 0.7 0.0± 0.0
CRFR2 ago 0.0± 0.0 4.6± 2.0 4.4± 2.2 0.6± 0.6 0.0± 0.0 2.6± 1.8 1.9± 1.9
CRFR2 ant 0.0± 0.0 2.3± 1.5 0.6± 0.6 0.0± 0.0 0.0± 0.0 0.0± 0.0 0.6± 0.6
The occurrence of all off-nest behaviors was scored for 60min before (averaged as basal) and 90min after drug infusion (immediately before t 0 min), as well as during an
additional 60min period in the afternoon. Off-nest behavior is further divided into locomotion (including digging/burrowing and any explorative behavior in the home cage),
self-grooming, and sleeping/resting. For details on treatments, see the Fig. 2 legend. Data are presented as group means ± SEM. n ¼ 6e8 rats per group. **p  0.01, *p  0.05
versus VEH; þþ p  0.01, þ p  0.05 versus basal.
Table 2
Effect of pharmacological manipulation of MPOA CRFR1 or CRFR2 on non-maternal
behaviors under stress conditions on LD 7.
Behavior Group Occurrence [n]
Basal 0min þ30 min
Off-nest VEH 4.7± 2.2 10.2± 1.8þþ 2.7± 1.2
CRFR1 ago 0.5± 0.2 11.0± 1.0þþ 8.0 ± 1.4*
CRFR1 ant 1.3± 0.2 8.7± 2.3þþ 2.0± 1.1
CRFR2 ago 4.5± 2.4 8.8± 2.0þ 4.7± 1.7
CRFR2 ant 2.9± 1.2 6.5± 2.2 4.7± 2.3
Locomotion VEH 1.3± 0.7 3.5± 1.8 0.7± 0.5
CRFR1 ago 0.1± 0.1 4.3± 0.7 3.0± 0.7
CRFR1 ant 0.2± 0.1 3.2± 0.7 0.0± 0.0
CRFR2 ago 0.4± 0.3 4.0± 1.6 1.7± 0.6
CRFR2 ant 0.6± 0.2 2.8± 0.9 0.8± 0.3
Self-grooming VEH 0.7± 0.2 1.5± 0.6 0.5± 0.3
CRFR1 ago 0.3± 0.1 5.0 ± 0.8**þþ 2.5 ± 1.3**
CRFR1 ant 0.2± 0.1 2.0± 0.9þ 0.0± 0.0
CRFR2 ago 0.8± 0.4 2.2± 0.8 0.7± 0.3
CRFR2 ant 0.5± 0.2 1.5± 0.4 1.0± 0.6
Sleeping/
resting
VEH 1.0± 1.0 3.5± 2.2 1.3± 1.3
CRFR1 ago 0.0± 0.0 0.5± 0.5 0.5± 0.5
CRFR1 ant 0.3± 0.3 1.8± 1.3 1.7± 1.0
CRFR2 ago 1.9± 1.3 0.0± 0.0 1.5± 1.5
CRFR2 ant 0.4± 0.3 1.7± 1.7 2.5± 2.5
The occurrence of all off-nest behaviors was scored for 60min before (averaged as
basal) and 60min after the infusion combined with the maternal defense test
(immediately before t 0 min). Off-nest behavior is further divided into locomotion
(including digging/burrowing and any explorative behavior in the home cage), self-
grooming, and sleeping/resting. For details on treatments, see the Fig. 2 legend. Data
are presented as group means ± SEM. n ¼ 6 rats per group. **p  0.01, *p  0.05
versus VEH; þþ p  0.01, þ p  0.05 versus basal.
Fig. 3. Effect of pharmacological manipulation of MPOA CRFR1 or CRFR2 on
maternal aggression in lactating rats. Maternal aggression against a virgin female
intruder was scored during a 10-min maternal defense test. The number of attacks
(left) and sum of aggressive behaviors (right) exhibited by the resident are shown. For
details on treatments, see the Fig. 2 legend. Data are presented as mean þ SEM. n ¼ 6
per group. **p < 0.01 versus VEH (one-way ANOVA; factor: treatment).
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ANOVA; F4,80¼ 5.60, p< 0.01) and treatment (F2,20¼ 4.27, p¼ 0.02;
Fig. 5A left) on ABN. The CRFR1 agonist-treated dams performed
signiﬁcantly less ABN after ICV drug infusion at t þ30 min
(p ¼ 0.05) and t þ60 min compared to the VEH-treated dams
(p ¼ 0.01). Additionally, the CRFR2 agonist-treated dams displayed
less ABN at t þ60 min compared to the VEH group (p ¼ 0.04).
Nursing: Nursing differed depending on time (two-way RM
ANOVA; F4,80¼ 4.62, p< 0.01), but not treatment (data not shown).
CRFR2 agonist-treated dams showed less nursing at t 0min
compared to the previous time point (p¼ 0.05).
Other maternal behavior: LG differed over time between the
treatment groups (two-way RM ANOVA; F8,80¼ 3.91, p< 0.01;
Fig. 5A right). CRFR1 agonist-treated rats displayed signiﬁcantly
more pup LG after drug infusion at t þ30 min (p < 0.01) and
t þ60 min (p ¼ 0.02) compared with the VEH-treated group. No
signiﬁcant differences were observed for pup retrieval/mouthing
(data not shown).
Non-maternal behavior: No differences were found for non-
maternal behaviors, i.e. off-nest behavior (data not shown).
3.3.2. Maternal care under stress conditions
No signiﬁcant differences were found for ABN, nursing, pup
retrieval/mouthing, and LG (data not shown).
3.3.3. Maternal aggression
No differences were found in aggressive behaviors between the
groups (data not shown).
3.3.4. Oxytocin release
The mean basal oxytocin release was 2.83 ± 0.73 pg/sample in
the VEH-, 2.88± 0.54 pg/sample in the CRFR1 agonist-, and
2.67± 0.31 pg/sample in the CRFR2 agonist-treated dams. There
was a signiﬁcant effect of time (two-way RM ANOVA; F4,72¼ 4.19,
p< 0.01) and treatment (F2,18¼ 4.40, p¼ 0.02; Fig. 5B) on oxytocin
release in the MPOA. Oxytocin release in the MPOA was signiﬁ-
cantly greater in the CRFR1 agonist-treated dams after drug infu-
sion at t þ30 min (p ¼ 0.02) compared to the VEH-treated dams.
3.4. Experiment 4: Intra-MPOA CRFR1 agonist retrodialysis and
oxytocin release in lactating rats
The mean basal oxytocin release was 1.73± 0.35 pg/sample in
the VEH- and 1.70± 0.42 pg/sample in the CRFR1 agonist-treated
dams. Oxytocin release in the MPOA changed signiﬁcantly over
time between the groups (two-way RM ANOVA; F4,48¼ 3.40,
p¼ 0.01; Fig. 5C). Oxytocin release was increased in the CRFR1
agonist-treated dams during (t 0 min: p < 0.01) and immediately
after drug administration (tþ30 min: p¼ 0.05), compared with the
VEH group.
3.5. Experiment 5: Intra-MPOA inhibition of CRFBP in lactating rats
Acute infusion of a CRFBP inhibitor into the MPOA had no effect
on maternal care (under non-stress or stress conditions), maternal
motivation, maternal aggression, or anxiety-related behavior (data
not shown).
4. Discussion
The brain CRF system is a potent regulator of maternal behavior.
In brain areas such as the lateral septum (D'Anna and Gammie,
2009; Gammie et al., 2004) and the BNST (Klampﬂ et al., 2014,
2016a, b) CRF plays a prominent role in impeding maternal
behavior by reducing maternal care and maternal aggression while
increasing anxiety. Thus, dampened CRFR activity in the peri-
partum period is crucial for high levels of maternal behavior and
low maternal anxiety and hence, for successful rearing of the
offspring.
Here, we advanced our current knowledge of the effects of an
active CRF system in limbic brain areas to the hypothalamic MPOA,
one of the most important brain regions for maternal behavior
(Numan and Insel, 2003). We provide evidence that CRFR, partic-
ularly CRFR1, in the MPOA are involved in the regulation of
maternal care, maternal aggression, and maternal anxiety inducing
maternal neglect upon activation. Interestingly, Crhr1 mRNA is
predominantly expressed in the MPOA compared to Crhr2. How-
ever, we did not ﬁnd a signiﬁcant difference in expression between
virgin and lactating rats suggesting that CRFR1 are not down-
regulated postpartum as a potential adaptive mechanism to
ensure reduced CRFR1 signal transduction.
Under non-stress conditions, ABN and total nursing were
reduced following infusion of VEH or either CRFR agonist into the
MPOA, which is consistent with our previous ﬁndings in the BNST
suggesting that the infusion might be perceived as a mild stressor
(Klampﬂ et al., 2014, 2016a). In addition, the behavioral proﬁle
following activation of MPOA CRFR is very similar to that observed
following stimulation of anterior-dorsal BNST CRFR (Klampﬂ et al.,
2016a). Indeed in both regions, CRFR1 stimulation strongly
decreased ABN and nursing, while CRFR2 activation induced amore
transient and less pronounced decline in ABN and nursing. How-
ever, it should be noted that the effect of the CRFR2 agonist in the
MPOA on ABN may be artiﬁcial, as it is only different from VEH at t
Fig. 4. Effect of pharmacological manipulation of MPOA CRFR1 or CRFR2 on anxiety-related behavior in lactating rats. The percent time spent on the open arms, the number
of full open arm entries and closed arm entries during the 5-min test are shown. For details on treatments, see the Fig. 2 legend. Data are presented as groupmeans þ SEM. n ¼ 6 per
group. *p < 0.05 versus VEH (one-way ANOVA; factor: treatment); #p < 0.05 versus VEH (independent t-test).
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0 min and t þ30 min due to the greater levels of ABN under basal
conditions in the VEH group. Nevertheless, both the CRFR1 and
CRFR2 agonists signiﬁcantly reduced total nursing behavior, and
this effect was not a result of different levels of nursing under basal
conditions. Moreover, the dams displayed signiﬁcantly more non-
maternal behaviors (i.e. off-nest behavior, locomotion, and self-
grooming) over the period where ABN and nursing were reduced
by the CRFR agonist treatments. Importantly, both CRFR antagonists
prevented the infusion-induced reduction in ABN indicating a role
for both receptors in the MPOA in the regulation of maternal care.
Under stress conditions, nursing was decreased while LG was
increased in the CRFR1 agonist-treated dams. LG is generally
considered a positive and beneﬁcial behavior by the dam directed
towards the pups (Champagne andMeaney, 2001), which is why an
increase in LG by CRFR1 activation might seem counter-intuitive.
However, CRF is well-known to induce self-grooming in both
males and females (Dunn et al., 1987; Wiersielis et al., 2016),
referred to as displacement activity (Kalueff et al., 2016). During
lactation, this activity seems to be redirected from self-grooming to
pup-grooming, thus increasing LG after stressor exposure. In sup-
port, a similar effect has been reported in lactating rats following
exposure to white noise stress (Windle et al., 1997b). Moreover,
inhibition of CRFR1 prevented the stress-induced reduction in ABN,
but not nursing. Given that the rescuing effect of the CRFR1
antagonist is limited to ABN, it is likely that any stress-induced
impairments in maternal care are mediated by CRFR in more
stress-responsive brain regions, such as the BNST (Klampﬂ et al.,
2014, 2016a).
Maternal motivation, as tested using the pup retrieval test, was
not affected by CRFR manipulation, similar to ﬁndings following
central and intra-BNST manipulations of CRFR in lactating rats
(Klampﬂ et al., 2013, 2014, 2016a) and those in CRFR-deﬁcient
lactating mice (Gammie et al., 2007). The MPOA is one of the ma-
jor brain regions involved in mediating maternal motivation
(Numan and Insel, 2003; Numan and Woodside, 2010), however
our ﬁnding that manipulating MPOA CRFR had no effect on this
appetitive behavior further strengthens our general premise that
the central CRF system is not involved in regulating maternal
motivation postpartum.
During the maternal defense test, there was a robust increase in
maternal aggression only in the dams administered the CRFR1
antagonist into the MPOA, indicating active CRFR1 during the
maternal defense test and thus, a prominent role for MPOA CRFR1
in the regulation of maternal aggression. To our knowledge, this is
Fig. 5. Effect of ICV or intra-MPOA CRFR activation on maternal care and oxytocin release in the MPOA of lactating rats. Arched back nursing (ABN) and licking/grooming (LG)
(A) as well as oxytocin release in the MPOA (B) were assessed for 60 min before (t 60 to t 30) and 90 min after ICV drug infusion (t 0 to t þ60) under non-stress conditions. (C)
Oxytocin release in the MPOA was measured for 60 min before (t 60 to t 30), 30 min during (t 0), and 60 min after (t þ30 to t þ60) retrodialysis.
For (A) and (B), dams received an acute ICV infusion of either (i) vehicle (VEH), (ii) CRFR1 agonist (ago; h/rCRF), or (iii) CRFR2 ago (hUcn3/stresscopin). For (C), dams received chronic
CRFR1 agonist retrodialysis into the MPOA. Data are presented as group means þ SEM. n ¼ 6e8 rats per group. **p  0.01, *p  0.05 versus VEH-treated group (two-way RM
ANOVA).
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the ﬁrst time a direct involvement of the MPOA in modulating
maternal aggression via a neurotransmitter system has been
demonstrated. To date, the MPOA has only been reported to show
increased neuronal activity upon an aggressive encounter in
lactating mice (Gammie and Nelson, 2001) and rats (Motta et al.,
2013). Furthermore, we are the ﬁrst to demonstrate a direct effect
of CRFR1 in regulating maternal aggression as previous studies
revealed an exclusive role for CRFR2 in this behavior within the
BNST (Klampﬂ et al., 2014) and lateral septum (D'Anna and
Gammie, 2009) of rats, and in CRFR2-deﬁcient mice (D'Anna
et al., 2008).
In addition to maternal behavior, stimulation of CRFR1 activity
within the MPOA had an anxiogenic effect. Indeed, the CRFR1
agonist, CRF, is well known to have anxiogenic actions in lactating
females (Klampﬂ et al., 2013, 2014) and males (Koob and Thatcher-
Britton, 1985). Interestingly, such an anxiogenic effect of CRF has
not been demonstrated within the MPOA, and this brain region is
not known to mediate anxiety-related behavior. However, in
contrast to studies demonstrating an anxiolytic effect of ICV
(Klampﬂ et al., 2013) or intra-BNST (Klampﬂ et al., 2014) CRFR1
blockade, inhibition of MPOA CRFR1 did not alter maternal anxiety.
On the one hand, this discrepancy might be explained by a ﬂoor
effect in the CRFR1 antagonist group as the dams' anxiety levels
were generally very low. On the other hand, this could point to an
indirect effect of CRFR1 activation on anxiety through reduced
locomotion. Indeed, the MPOA is neuronally interconnected with
the zona incerta and the pedunculopontine nucleus, brain areas
that are involved in mediating locomotion (Swanson et al., 1987).
Thus, decreased locomotion may result in less time spent on the
open arms of the EPM, which is typically interpreted as increased
anxiety, but may rather be an indirect consequence. Nevertheless, it
remains possible that CRF's effect on anxiety seen here was a direct
action, as ICV CRF infusion in novel environments (such as the EPM)
can decrease general locomotor activity (Baldwin et al., 1991; Koob
and Heinrichs, 1999). Hence, further studies are needed to closely
delineate the effects of CRFR1 activation on maternal anxiety from
those on general activity.
Since previous studies have demonstrated neuronal interactions
between the CRF and oxytocin systems (Bosch et al., 2016;
Dabrowska et al., 2011, 2013; Windle et al., 2004), we investigated
whether an interaction between these two systems could shed light
on the down-stream mechanism through which CRFR activation
impairs maternal behavior. Given that oxytocin is known to pro-
mote the onset and maintenance of maternal care (Bosch and
Neumann, 2012; Numan and Insel, 2003) and administration of
an oxytocin receptor antagonist into the MPOA decreases ABN
(Pedersen et al., 1994), we hypothesized that activation of central
CRFR would reduce oxytocin release in the MPOA and hence impair
maternal care. However, contrary to our prediction a single acute
ICV infusion, as well as intra-MPOA retrodialysis, of a CRFR1 agonist
increased oxytocin release in the MPOA under non-stress condi-
tions. This seemed to be speciﬁc to theMPOA given that the effect of
the CRFR1 agonist on oxytocin release was similar regardless of
whether the drug was given centrally (experiment 3) or locally
(experiment 4) into the MPOA. As oxytocin is released upon
stressor exposure to reduce the hypothalamo-pituitary-adrenal
axis response (Windle et al., 1997a), it is feasible that oxytocin is
released upon CRFR1 activation in the MPOA to counteract CRF's
effects on maternal behavior and ultimately loop back to regulate
CRF neurons in the MPOA. Indeed, in the PVN oxytocin has been
shown to reduce CrhmRNA (Bulbul et al., 2011; Windle et al., 2004)
and stress-induced Fos expression (Windle et al., 2004), to delay
the stress-induced rise in Crh transcription (Jurek et al., 2015), and
to modulate CRF neuronal excitability (Jamieson et al., 2017).
Moreover, stress-induced social buffering requires prolonged
oxytocin release within the PVN, thereby inducing faster stress
recovery in female prairie voles (Smith and Wang, 2014) and sup-
porting a role for oxytocin in terminating the stress response. Thus,
oxytocin release might be triggered by CRFR1 activation in the
MPOA as a rescuing mechanism to minimize a reduction in
maternal behavior and help provide stable levels of care for the
offspring. However to date, little is known about neuronal in-
teractions between the CRF and oxytocin systems in the MPOA.
Even though CRF and oxytocin are co-expressed in some hypo-
thalamic structures (Meister, 1993), neither cells nor ﬁbres of these
peptides co-localize in the MPOA, at least in male rats (Simerly and
Swanson, 1988). Thus, it seems more likely that both CRF and
oxytocin are not released upon the same stimulation from the same
neuronal population, but rather that oxytocin is released after CRF
has bound to and activated CRFR1. Similar interactions have
recently been described in male prairie voles (Bosch et al., 2016;
Pohl et al., 2018); activation of central CRFR2 suppresses, while
inhibition of central CRFR2 increases, oxytocin release in the nu-
cleus accumbens from neurons originating in the PVN. Further
experiments investigating potential sites of CRFR1 and oxytocin co-
expression would enhance our understanding of the mechanisms
underlying the interactions between the CRF and oxytocin systems
in the MPOA, and their impact on maternal behavior.
Given that Crhr1 and Crhr2mRNA levels are unchanged and Crh
mRNA expression is in fact elevated in lactation (Walker et al.,
2001), we postulated that CRFBP, whose expression is increased
by stress (Lombardo et al., 2001; McClennen et al., 1998; Westphal
and Seasholtz, 2006), might be important for minimizing CRFR
activity. However, we did not ﬁnd any effects of inhibiting CRFBP in
the MPOA on maternal or anxiety-like behaviors, neither did we
detect any change in Crhbp mRNA expression during lactation that
would support such a role. It is unlikely that the dose used was too
low to fully inhibit CRFBP in the MPOA, as the same dose admin-
istered into the BNST elicits behavioral changes (Klampﬂ et al.,
2016b), and there is no indication that CRFBP concentrations in
the MPOA differ markedly from those in the BNST. Rather, it seems
more likely that CRFBP in the MPOA is not involved in dampening
the activity of the CRF system postpartum.
In conclusion, we report that activation of CRFR, particularly
CRFR1, in the MPOA impedes maternal care and maternal aggres-
sion and increases maternal anxiety. Furthermore, CRFBP does not
appear to be involved in the crucial down-regulation of the CRF
system postpartum. Yet, we identiﬁed another potential regulatory
mechanism involving oxytocin release in the MPOA, which may
serve to counteract the effects of CRFR activation, thereby ensuring
stable levels of maternal behavior. Interestingly, this mechanism
might be disturbed in mothers showing stress-induced maternal
neglect and represents a potential target for treating such mal-
functions in the postpartum period.
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